NUVL vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs.
Nuvalent (NASDAQ:NUVL) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Nuvalent has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Nuvalent. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 10 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.21 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Nuvalent is being referred to more favorably in the media.
97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Nuvalent presently has a consensus target price of $113.10, indicating a potential upside of 50.84%. Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 49.13%. Given Nuvalent's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries received 1288 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Nuvalent's return on equity.
Nuvalent has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Summary
Nuvalent beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy NUVL Stock Free NUVL Stock Alerts